Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 3/20 | 0.38 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919962 | 0.88 | MAP2K1 (0.47) | PKMELANEMAP2K1MAP2K2MAPT | |
| SCHEMBL1920042 | 0.88 | MAP2K1 (0.50) | PKMELANEMAP2K1MAP2K2 | |
| SCHEMBL1920033 | 0.86 | MAP2K1 (0.38) | PKMBRAFEIF2AK3MAP2K1MAP2K2 | |
| SCHEMBL1921170 | 0.85 | ELANE (0.41) | PKMELANEBRAFEIF2AK3MAP2K1 | |
| SCHEMBL1920604 | 0.84 | MAP2K1 (0.36) | PKMBRAFEIF2AK3MAP2K1MAP2K2 | |
| SCHEMBL1920479 | 0.83 | PKM (0.38) | PKMMAP2K1MAP2K2TSHRMAPT | |
| SCHEMBL2566055 | 0.79 | MAP2K1 (0.53) | BRAFEIF2AK3MAP2K1TSHRMAPT | |
| SCHEMBL1922052 | 0.79 | GAA (0.44) | PKMELANEBRAFEIF2AK3MAP2K1 | |
| SCHEMBL1920337 | 0.79 | MAPT (0.43) | TSHRMAPTSMN1; SMN2 | |
| SCHEMBL1920301 | 0.78 | MAP2K1 (0.47) | ELANEMAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099796-B1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855216-B2 | Aza-indolyl compounds and methods of use | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242655-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | CDKN1A, MKI67, CCNI | PKM 2196/4885ELANE 910/4885BRAF 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.